Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 108

    1.

    Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice.

    Zhou M, Kostoula I, Brill B, Panou E, Sakarellos-Daitsiotis M, Dietrich U.

    Vaccine. 2012 Mar 2;30(11):1911-6. Epub 2012 Jan 23.

    PMID:
    22269872
    [PubMed - in process]
    2.

    Monitoring HPV type-specific prevalence over time through clinic-based surveillance: a perspective on vaccine effectiveness.

    Gaffga NH, Flagg EW, Weinstock HS, Shlay JC, Ghanem KG, Koutsky LA, Kerndt PR, Hsu KK, Unger ER, Datta SD.

    Vaccine. 2012 Mar 2;30(11):1959-64. Epub 2012 Jan 18.

    PMID:
    22265859
    [PubMed - in process]
    3.

    HIV vaccine candidates generate in vitro T cell response to putative epitopes in Chinese-origin rhesus macaques.

    Liao Q, Strong AJ, Liu Y, Liu Y, Meng P, Fu Y, Touzjian N, Shao Y, Zhao Z, Lu Y.

    Vaccine. 2012 Feb 21;30(9):1601-8. Epub 2012 Jan 17.

    PMID:
    22261410
    [PubMed - in process]
    4.

    Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

    Cox JH, Ferrari MG, Earl P, Lane JR, Jagodzinski LL, Polonis VR, Kuta EG, Boyer JD, Ratto-Kim S, Eller LA, Pham DT, Hart L, Montefiori D, Ferrari G, Parrish S, Weiner DB, Moss B, Kim JH, Birx D, VanCott TC.

    Vaccine. 2012 Feb 27;30(10):1830-40. Epub 2012 Jan 9.

    PMID:
    22234262
    [PubMed - in process]
    5.

    Vaccines of the future.

    Nossal GJ.

    Vaccine. 2011 Dec 30;29 Suppl 4:D111-5. Epub 2011 Dec 18.

    PMID:
    22185835
    [PubMed - in process]
    6.

    A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.

    Tang J, Yin R, Tian Y, Huang Z, Shi J, Fu X, Wang L, Wu Y, Hao F, Ni B.

    Vaccine. 2012 Feb 1;30(6):1071-82. Epub 2011 Dec 15.

    PMID:
    22178528
    [PubMed - indexed for MEDLINE]
    7.

    SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.

    Lai L, Kwa SF, Kozlowski PA, Montefiori DC, Nolen TL, Hudgens MG, Johnson WE, Ferrari G, Hirsch VM, Felber BK, Pavlakis GN, Earl PL, Moss B, Amara RR, Robinson HL.

    Vaccine. 2012 Feb 21;30(9):1737-45. Epub 2011 Dec 15.

    PMID:
    22178526
    [PubMed - in process]
    8.

    Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.

    Hakim H, Allison KJ, Van De Velde LA, Li Y, Flynn PM, McCullers JA.

    Vaccine. 2012 Jan 20;30(5):879-85. Epub 2011 Dec 9.

    PMID:
    22155630
    [PubMed - indexed for MEDLINE]
    9.

    Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

    Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, Khan WN, Kornbluth RS, Stone GW.

    Vaccine. 2012 Jan 17;30(4):691-702. Epub 2011 Dec 4.

    PMID:
    22146759
    [PubMed - indexed for MEDLINE]
    10.

    An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

    Ahmed FK, Clark BE, Burton DR, Pantophlet R.

    Vaccine. 2012 Jan 20;30(5):922-30. Epub 2011 Dec 4.

    PMID:
    22142583
    [PubMed - indexed for MEDLINE]
    11.

    Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys.

    Kaufman DR, Li F, Cruz AN, Self SG, Barouch DH.

    Vaccine. 2012 Jan 11;30(3):506-9. Epub 2011 Nov 29.

    PMID:
    22133509
    [PubMed - indexed for MEDLINE]
    12.

    Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009.

    von Gottberg A, Cohen C, Whitelaw A, Chhagan M, Flannery B, Cohen AL, de Gouveia L, Plessis Md, Madhi SA, Klugman KP; Group for Enteric, Respiratory, Meningeal Disease Surveillance in South Africa (GERMS-SA).

    Vaccine. 2012 Jan 11;30(3):565-71. Epub 2011 Nov 26.

    PMID:
    22119925
    [PubMed - indexed for MEDLINE]
    13.

    Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.

    Ali Tabei SM, Li Y, Weigert M, Dinner AR.

    Vaccine. 2012 Jan 11;30(3):607-13. Epub 2011 Nov 23.

    PMID:
    22119591
    [PubMed - indexed for MEDLINE]
    14.

    HIV vaccine development: Challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.

    Koff WC.

    Vaccine. 2011 Nov 17. [Epub ahead of print]

    PMID:
    22100891
    [PubMed - as supplied by publisher]
    15.

    HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E.

    Paris R, Bejrachandra S, Thongcharoen P, Nitayaphan S, Pitisuttithum P, Sambor A, Gurunathan S, Francis D, Ratto-Kim S, Karnasuta C, de Souza MS, Polonis VR, Brown AE, Kim JH, Stephens HA; Thai AIDS Vaccine Evaluation Group.

    Vaccine. 2012 Jan 20;30(5):832-6. Epub 2011 Nov 12.

    PMID:
    22085554
    [PubMed - indexed for MEDLINE]
    16.

    HIV-1 and influenza antigens synthetically linked to IgG2a Fc elicit superior humoral responses compared to unmodified antigens in mice.

    Zaharatos GJ, Yu J, Pace C, Song Y, Vasan S, Ho DD, Huang Y.

    Vaccine. 2011 Dec 9;30(1):42-50. Epub 2011 Nov 4.

    PMID:
    22064264
    [PubMed - indexed for MEDLINE]
    17.

    TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques.

    Sui Y, Gagnon S, Dzutsev A, Zhu Q, Yu H, Hogg A, Wang Y, Xia Z, Belyakov IM, Venzon D, Klinman D, Strober W, Kelsall B, Franchini G, Berzofsky JA.

    Vaccine. 2011 Dec 9;30(1):59-68. Epub 2011 Oct 29.

    PMID:
    22041305
    [PubMed - indexed for MEDLINE]
    18.

    Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.

    Bialuk I, Whitney S, Andresen V, Florese RH, Nacsa J, Cecchinato V, Valeri VW, Heraud JM, Gordon S, Parks RW, Montefiori DC, Venzon D, Demberg T, Guroff MR, Landucci G, Forthal DN, Franchini G.

    Vaccine. 2011 Dec 9;30(1):78-94. Epub 2011 Oct 27.

    PMID:
    22037204
    [PubMed - indexed for MEDLINE]
    19.

    Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication.

    Pallikkuth S, Rogers K, Villinger F, Dosterii M, Vaccari M, Franchini G, Pahwa R, Pahwa S.

    Vaccine. 2011 Nov 15;29(49):9229-38. Epub 2011 Oct 11.

    PMID:
    21996099
    [PubMed - indexed for MEDLINE]
    20.

    Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults.

    Hatakeyama S, Iwatsuki-Horimoto K, Okamoto K, Nukui Y, Yata N, Fujita A, Inaba S, Yotsuyanagi H, Kawaoka Y.

    Vaccine. 2011 Nov 15;29(49):9224-8. Epub 2011 Oct 5.

    PMID:
    21978767
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk